Gastroenterology
Volume 137, Issue 3 , Pages 986-996, September 2009

ErbB Signaling Is Required for the Proliferative Actions of GLP-2 in the Murine Gut

Department of Medicine, Samuel Lunenfeld Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

Received 1 October 2008; accepted 29 May 2009. published online 11 June 2009.

Background & Aims

Glucagon-like peptide-2 (GLP-2) is a 33-amino acid peptide hormone secreted by enteroendocrine cells in response to nutrient ingestion. GLP-2 stimulates crypt cell proliferation leading to expansion of the mucosal epithelium; however, the mechanisms transducing the trophic effects of GLP-2 are incompletely understood.

Methods

We examined the gene expression profiles and growth-promoting actions of GLP-2 in normal mice in the presence or absence of an inhibitor of ErbB receptor signaling, in Glp2r−/− mice and in Egfrwa2 mice harboring a hypomorphic point mutation in the epidermal growth factor receptor.

Results

Exogenous GLP-2 administration rapidly induced the expression of a subset of ErbB ligands including amphiregulin, epiregulin, and heparin binding (HB)-epidermal growth factor, in association with induction of immediate early gene expression in the small and large bowel. These actions of GLP-2 required a functional GLP-2 receptor because they were eliminated in Glp2r−/− mice. In contrast, insulin-like growth factor-I and keratinocyte growth factor, previously identified mediators of GLP-2 action, had no effect on the expression of these ErbB ligands. The GLP-2-mediated induction of ErbB ligand expression was not metalloproteinase inhibitor sensitive but was significantly diminished in Egfrwa2 mice and completed abrogated in wild-type mice treated with the pan-ErbB inhibitor CI-1033. Furthermore, the stimulatory actions of GLP-2 on crypt cell proliferation and bowel growth were eliminated in the presence of CI-1033.

Conclusions

These findings identify the ErbB signaling network as a target for GLP-2 action leading to stimulation of growth factor-dependent signal transduction and bowel growth in vivo.

Abbreviations used in this paper: EGF, epidermal growth factor, EGFR, epidermal growth factor receptor, GLP, glucagon-like peptide, IGF-I, insulin-like growth factor-I, KGF, keratinocyte growth factor

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Conflicts of interest The authors disclose the following: Dr Drucker is a party, together with the University of Toronto and the University Health Network, in a GLP-2 licensing agreement with NPS Pharmaceuticals Inc. The remaining authors disclose no conflicts.

 Funding Supported in part by an operating grant from CIHR MOP-14799 and from the National Cancer Institute of Canada, grant 017428; by the Canadian Cancer Society; and by a Canada Research Chair in Regulatory Peptides (to D.J.D.).

PII: S0016-5085(09)00905-6

doi:10.1053/j.gastro.2009.05.057

Gastroenterology
Volume 137, Issue 3 , Pages 986-996, September 2009